iifl-logo

Aurobindo Pharma Ltd Key Ratios

Add as a Preferred Source on Google
1,206.2
(-0.43%)
Dec 26, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-5.32

7.25

40.3

10.41

Op profit growth

-17.74

9.64

28.96

9.82

EBIT growth

-23.14

13.92

23.21

6.28

Net profit growth

-50.36

88.44

16.82

5.27

Profitability ratios (%)

OPM

18.7

21.52

21.05

22.91

EBIT margin

15.26

18.8

17.7

20.15

Net profit margin

11.29

21.53

12.25

14.71

RoCE

12.79

18.29

20.44

21.98

RoNW

2.84

6.88

4.96

5.75

RoA

2.36

5.23

3.53

4.01

Per share ratios (₹)

EPS

45.18

91.04

48.54

41.35

Dividend per share

9

4

3

2.5

Cash EPS

25.96

73.03

31.81

31.83

Book value per share

419.42

374.28

287.15

199.35

Valuation ratios

P/E

14.8

9.68

8.5

13.47

P/CEPS

25.75

12.06

12.98

17.5

P/B

1.59

2.35

1.43

2.79

EV/EBIDTA

8.04

9.01

5.37

9.32

Payout (%)

Dividend payout

9.95

0

0

6.04

Tax payout

-20.54

-43.83

-24.13

-25.24

Liquidity ratios

Debtor days

58.47

57.59

58.43

64.8

Inventory days

129.16

123.32

107.12

112.94

Creditor days

-58.64

-55.93

-53.39

-70.89

Leverage ratios

Interest coverage

-73.61

-62.54

-13.4

-42.7

Net debt / equity

-0.05

0

0.17

0.3

Net debt / op. profit

-0.3

-0.02

0.61

0.92

Cost breakup (₹)

Material costs

-43.23

-39.97

-42.14

-41.01

Employee costs

-14.71

-14.26

-13.93

-12.94

Other costs

-23.35

-24.23

-22.85

-23.12

Aurobindo Pharma : related Articles

Aurobindo Pharma Raises Luoxin Aurovitas Stake to 50% With $5.12 Million Deal

The acquisition is expected to be completed within the next three months and is aimed at expanding manufacturing capacity at the facility to meet rising market demand.

23 Dec 2025|03:39 PM
Read More
Aurobindo Pharma Gets USFDA Form 483 for Unit IV, Shares Gain 1.5%

The inspection at the Andhra Pradesh facility was carried out between December 8 and December 17, 2025.

18 Dec 2025|12:13 PM
Read More
Top Stocks for Today - 15th December 2025

Here are some of the stocks that may see significant price movements today: Wipro, Godawari Power & Ispat, KEC International, etc.

15 Dec 2025|09:06 AM
Read More
Top Stocks for Today - 8th September 2025

Here are some of the stocks that may see significant price movement today: Aurobindo Pharma, Vedanta, Adani Power, etc.

8 Sep 2025|07:26 AM
Read More
Aurobindo Pharma Q1 Updates: Net Profit slips 10.20% y-o-y

The company announced an operating EBITDA of ₹1,603 Crore, registering a marginal decline of 1% year-on-year.

5 Aug 2025|01:15 PM
Read More
Top Stocks for Today - 5th August 2025

Here are some of the stocks that may see significant price movement today: LTIMindtree, Paytm, Aurobindo Pharma, etc.

5 Aug 2025|09:00 AM
Read More
Aurobindo Pharma to Acquire U.S.-based Lannett for $250 Million

Lannett is a legacy pharmaceutical firm founded in 1942.  It is headquartered in Trevose, Pennsylvania, brings with it a deep expertise in manufacturing complex generics.

31 Jul 2025|09:19 AM
Read More
Top Stocks for Today - 3rd July 2025

Here are some of the stocks that may see significant price movement today: FSN E-Commerce, Voltas Limited, Aurobindo Pharma, etc.

3 Jul 2025|06:42 AM
Read More
Aurobindo Pharma’s Arm CuraTeQ Gets MHRA Nod for Dyrupeg

Dyrupeg is used primarily to reduce the risk of infection in cancer patients undergoing chemotherapy.

26 Jun 2025|12:55 PM
Read More
Top Stocks for Today - 27th May 2025

Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.

27 May 2025|06:36 AM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.